Open Payments

Boston Medical Center

Type
Teaching hospital
Where
South Boston, MA
Medicare CCN
220031
Received
$6,140,129 in 507 records, 2020 ($1,570,437 general, $4,569,692 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2020General payment72$1,570,437
2020Research payment435$4,569,692

By company

CompanyRecordsAmountYears
PFIZER INC.52$2,375,5182020
Gilead Sciences, Inc.9$747,5262020
Merck Sharp & Dohme LLC40$543,4822020
ABBVIE INC.2$400,8952020
Karyopharm Therapeutics Inc.9$299,7922020
Regeneron Pharmaceuticals, Inc.5$170,8942020
VERTEX PHARMACEUTICALS INCORPORATED5$147,1432020
Alexion Pharmaceuticals, Inc.28$138,5122020
Janssen Research & Development, LLC21$135,3892020
Abbott Laboratories13$100,2632020
KARL STORZ Endoscopy-America25$94,1962020
Novo Nordisk AS153$81,6972020
Chugai Pharmaceutical Co., Ltd.1$81,5312020
Novo Nordisk Inc3$80,8142020
Amgen Inc.1$69,9592020
C. R. Bard, Inc. & Subsidiaries2$65,4472020
Biogen, Inc.1$59,4812020
Lexicon Pharmaceuticals, Inc.2$58,5552020
GE HEALTHCARE2$47,1382020
Philips North America LLC2$39,3422020
Laminate Medical Technologies inc.3$34,8632020
SANOFI US SERVICES INC.1$30,0002020
Takeda Pharmaceuticals U.S.A., Inc.15$26,1542020
Bayer Healthcare Pharmaceuticals Inc.8$23,9492020
EMD Serono, Inc.6$22,1592020
Baxter Healthcare1$21,8502020
Roche TCRC, Inc.5$20,9402020
Indivior Inc.4$20,0002020
Medtronic USA, Inc.1$19,5002020
Intercept Pharmaceuticals, Inc.9$18,5312020
Celgene Corporation2$17,0092020
Incyte Corporation11$16,1252020
Roche Diagnostics Operations, Inc.4$14,0912020
Boston Scientific Corporation2$13,7082020
Akcea Therapeutics, Inc.1$12,0712020
ViiV Healthcare Company3$12,0252020
Richard Wolf Medical Instruments Corp.1$10,0002020
Olympus Corporation of the Americas3$8,6632020
Bioptics, Inc.1$8,3122020
Aesculap, Inc.17$7,9392020
Conformis, Inc.3$6,9552020
GLOBAL BLOOD THERAPEUTICS, INC.3$5,2732020
ROCHE MOLECULAR SYSTEMS, INC.1$4,8752020
Boehringer Ingelheim Pharmaceuticals, Inc.2$4,5902020
AstraZeneca UK Limited2$3,7752020
Emergent BioSolutions Inc.2$3,5002020
Exelixis Inc.5$3,3912020
E.R. Squibb & Sons, L.L.C.3$2,6002020
Adaptive Biotechnologies Corporation1$2,2502020
Verastem, Inc.2$1,7642020

By nature of payment

NatureRecordsAmount
Research payment435$4,569,692
Grant12$1,015,930
Charitable Contribution9$406,206
Education25$94,196
Compensation for services other than consulting, including serving as faculty or as a speaker at a v7$22,948
Consulting Fee1$21,850
Gift18$9,306

Records

DateCompanyAmountNatureFormProductStudyYear
2020-12-31Gilead Sciences, Inc.$324,755GrantCash or cash equivalent2020
2020-12-31Philips North America LLC$33,974Research paymentCash or cash equivalent(6260) Ingenia 3 0T R5 Device, Neurology2020
2020-12-31Abbott Laboratories$33,115Research paymentIn-kind items and servicesArchitect SARS-CoV-2 IgM Device, DiagnosticsPerformance Evaluation of ARCHITECT SARS-CoV-2 IgM2020
2020-12-31KARL STORZ Endoscopy-America$26,370EducationIn-kind items and servicesAIDA HD CONNECT, DVD,WITH SMARTSCREEN,CE Device, OR12020
2020-12-31Abbott Laboratories$18,200Research paymentIn-kind items and servicesArchitect SARS-CoV-2 IgM Device, DiagnosticsPerformance Evaluation of ARCHITECT SARS-CoV-2 IgM2020
2020-12-31Roche Diagnostics Operations, Inc.$10,751Research paymentCash or cash equivalentCD cobas Reagents Device, Centralized DiagnosticsRD0014692020
2020-12-31KARL STORZ Endoscopy-America$8,318EducationIn-kind items and servicesAIDA HD CONNECT, DVD,WITH SMARTSCREEN,CE Device, OR12020
2020-12-31KARL STORZ Endoscopy-America$7,346EducationIn-kind items and servicesAIDA HD CONNECT, DVD,WITH SMARTSCREEN,CE Device, OR12020
2020-12-31Abbott Laboratories$6,500Research paymentIn-kind items and servicesArchitect SARS-CoV-2 IgM Device, DiagnosticsPerformance Evaluation of ARCHITECT SARS-CoV-2 IgM2020
2020-12-31KARL STORZ Endoscopy-America$6,090EducationIn-kind items and servicesAIDA HD CONNECT, DVD,WITH SMARTSCREEN,CE Device, OR12020
2020-12-31KARL STORZ Endoscopy-America$5,953EducationIn-kind items and servicesAIDA HD CONNECT, DVD,WITH SMARTSCREEN,CE Device, OR12020
2020-12-31KARL STORZ Endoscopy-America$5,600EducationIn-kind items and servicesAIDA HD CONNECT, DVD,WITH SMARTSCREEN,CE Device, OR12020
2020-12-31KARL STORZ Endoscopy-America$4,438EducationIn-kind items and servicesAIDA HD CONNECT, DVD,WITH SMARTSCREEN,CE Device, OR12020
2020-12-31KARL STORZ Endoscopy-America$4,084EducationIn-kind items and servicesAIDA HD CONNECT, DVD,WITH SMARTSCREEN,CE Device, OR12020
2020-12-31KARL STORZ Endoscopy-America$3,733EducationIn-kind items and servicesAIDA HD CONNECT, DVD,WITH SMARTSCREEN,CE Device, OR12020
2020-12-31Abbott Laboratories$3,090Research paymentIn-kind items and servicesArchitect SARS-CoV-2 IgM Device, DiagnosticsPerformance Evaluation of ARCHITECT SARS-CoV-2 IgM2020
2020-12-31KARL STORZ Endoscopy-America$2,834EducationIn-kind items and servicesAIDA HD CONNECT, DVD,WITH SMARTSCREEN,CE Device, OR12020
2020-12-31KARL STORZ Endoscopy-America$2,691EducationIn-kind items and servicesAIDA HD CONNECT, DVD,WITH SMARTSCREEN,CE Device, OR12020
2020-12-31KARL STORZ Endoscopy-America$2,661EducationIn-kind items and services26 inch LED MONITOR Device, VIDEOIMAGING2020
2020-12-31KARL STORZ Endoscopy-America$2,634EducationIn-kind items and servicesAIDA HD CONNECT, DVD,WITH SMARTSCREEN,CE Device, OR12020
2020-12-31KARL STORZ Endoscopy-America$2,634EducationIn-kind items and servicesAIDA HD CONNECT, DVD,WITH SMARTSCREEN,CE Device, OR12020
2020-12-31KARL STORZ Endoscopy-America$2,405EducationIn-kind items and servicesAIDA HD CONNECT, DVD,WITH SMARTSCREEN,CE Device, OR12020
2020-12-31Abbott Laboratories$2,343Research paymentIn-kind items and servicesArchitect SARS-CoV-2 IgM Device, DiagnosticsPerformance Evaluation of ARCHITECT SARS-CoV-2 IgM2020
2020-12-31KARL STORZ Endoscopy-America$2,008EducationIn-kind items and servicesAIDA HD CONNECT, DVD,WITH SMARTSCREEN,CE Device, OR12020
2020-12-31KARL STORZ Endoscopy-America$1,746EducationIn-kind items and servicesAIDA HD CONNECT, DVD,WITH SMARTSCREEN,CE Device, OR12020
2020-12-31Stryker Corporation$1,366GiftCash or cash equivalentNONE Device, NONE2020
2020-12-31KARL STORZ Endoscopy-America$1,056EducationIn-kind items and servicesAIDA HD CONNECT, DVD,WITH SMARTSCREEN,CE Device, OR12020
2020-12-31KARL STORZ Endoscopy-America$636EducationIn-kind items and servicesAIDA HD CONNECT, DVD,WITH SMARTSCREEN,CE Device, OR12020
2020-12-31Roche Diagnostics Operations, Inc.$443Research paymentIn-kind items and servicesCD cobas Reagents Device, Centralized DiagnosticsRD0014692020
2020-12-31KARL STORZ Endoscopy-America$365EducationIn-kind items and servicesAIDA HD CONNECT, DVD,WITH SMARTSCREEN,CE Device, OR12020
2020-12-31KARL STORZ Endoscopy-America$245EducationIn-kind items and servicesAIDA HD CONNECT, DVD,WITH SMARTSCREEN,CE Device, OR12020
2020-12-31KARL STORZ Endoscopy-America$163EducationIn-kind items and servicesAIDA HD CONNECT, DVD,WITH SMARTSCREEN,CE Device, OR12020
2020-12-31Abbott Laboratories$150Research paymentIn-kind items and servicesArchitect SARS-CoV-2 IgM Device, DiagnosticsPerformance Evaluation of ARCHITECT SARS-CoV-2 IgM2020
2020-12-31Abbott Laboratories$99Research paymentIn-kind items and servicesArchitect SARS-CoV-2 IgM Device, DiagnosticsPerformance Evaluation of ARCHITECT SARS-CoV-2 IgM2020
2020-12-31KARL STORZ Endoscopy-America$75EducationIn-kind items and services26 inch LED MONITOR Device, VIDEOIMAGING2020
2020-12-31KARL STORZ Endoscopy-America$74EducationIn-kind items and servicesAIDA HD CONNECT, DVD,WITH SMARTSCREEN,CE Device, OR12020
2020-12-31KARL STORZ Endoscopy-America$25EducationIn-kind items and servicesAIDA HD CONNECT, DVD,WITH SMARTSCREEN,CE Device, OR12020
2020-12-30PFIZER INC.$15,582Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-12-28Regeneron Pharmaceuticals, Inc.$69,143Research paymentCash or cash equivalentA Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies fo2020
2020-12-23PFIZER INC.$3,188Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-12-22Novo Nordisk AS$6,102Research paymentCash or cash equivalentOzempic Drug, DiabetesNN9535-43522020
2020-12-22Indivior Inc.$5,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentSUBLOCADE Drug, OUD2020
2020-12-21Janssen Research & Development, LLC$2,964Research paymentCash or cash equivalentRandomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez2020
2020-12-21Bayer Healthcare Pharmaceuticals Inc.$871Research paymentCash or cash equivalentMirena Drug, Women's HealthBAY86-5028 Mirena extension contraception2020
2020-12-21Novo Nordisk AS$123Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522020
2020-12-17PFIZER INC.$8,287Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA2020
2020-12-17Intercept Pharmaceuticals, Inc.$2,355Research paymentCash or cash equivalentOCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY10118662020
2020-12-16PFIZER INC.$5,783Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-12-15Merck Sharp & Dohme LLC$2,826Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A2020
2020-12-15Alexion Pharmaceuticals, Inc.$2,371Research paymentCash or cash equivalentSoliris Drug, ImmunologySOLIRIS (eculizumab) for the Treatment of Participants with Coronavirus Disease 2019 (COVID-19) An Expanded Access Progr2020
2020-12-15Alexion Pharmaceuticals, Inc.$2,288Research paymentCash or cash equivalentSoliris Drug, ImmunologySOLIRIS (eculizumab) for the Treatment of Participants with Coronavirus Disease 2019 (COVID-19) An Expanded Access Progr2020
2020-12-15Alexion Pharmaceuticals, Inc.$2,275Research paymentCash or cash equivalentSoliris Drug, ImmunologySOLIRIS (eculizumab) for the Treatment of Participants with Coronavirus Disease 2019 (COVID-19) An Expanded Access Progr2020
2020-12-15Alexion Pharmaceuticals, Inc.$2,275Research paymentCash or cash equivalentSoliris Drug, ImmunologySOLIRIS (eculizumab) for the Treatment of Participants with Coronavirus Disease 2019 (COVID-19) An Expanded Access Progr2020
2020-12-15Alexion Pharmaceuticals, Inc.$2,275Research paymentCash or cash equivalentSoliris Drug, ImmunologySOLIRIS (eculizumab) for the Treatment of Participants with Coronavirus Disease 2019 (COVID-19) An Expanded Access Progr2020
2020-12-15Alexion Pharmaceuticals, Inc.$2,275Research paymentCash or cash equivalentSoliris Drug, ImmunologySOLIRIS (eculizumab) for the Treatment of Participants with Coronavirus Disease 2019 (COVID-19) An Expanded Access Progr2020
2020-12-15Alexion Pharmaceuticals, Inc.$2,275Research paymentCash or cash equivalentSoliris Drug, ImmunologySOLIRIS (eculizumab) for the Treatment of Participants with Coronavirus Disease 2019 (COVID-19) An Expanded Access Progr2020
2020-12-15Alexion Pharmaceuticals, Inc.$2,275Research paymentCash or cash equivalentSoliris Drug, ImmunologySOLIRIS (eculizumab) for the Treatment of Participants with Coronavirus Disease 2019 (COVID-19) An Expanded Access Progr2020
2020-12-15Alexion Pharmaceuticals, Inc.$1,426Research paymentCash or cash equivalentSoliris Drug, ImmunologySOLIRIS (eculizumab) for the Treatment of Participants with Coronavirus Disease 2019 (COVID-19) An Expanded Access Progr2020
2020-12-14Merck Sharp & Dohme LLC$118,672Research paymentCash or cash equivalentJANUVIA Drug, ENDOCRINOLOGYEffects of SGLT2 inhibition on cardiac mitochondrial function, energetics and remodeling in non-diabetic mice with heart2020
2020-12-12PFIZER INC.$3,188Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-12-11VERTEX PHARMACEUTICALS INCORPORATED$11,839Research paymentCash or cash equivalentA Natural History Study of Patients With Biopsy-proven Focal Segmental Glomerulosclerosis and Proteinuria Who Are of Rec2020
2020-12-11Novo Nordisk AS$123Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522020
2020-12-10Aesculap, Inc.$3,684GiftCash or cash equivalent2020
2020-12-10Aesculap, Inc.$1,023GiftCash or cash equivalent2020
2020-12-10Aesculap, Inc.$586GiftCash or cash equivalent2020
2020-12-10Aesculap, Inc.$490GiftCash or cash equivalent2020
2020-12-10Aesculap, Inc.$430GiftCash or cash equivalent2020
2020-12-10Aesculap, Inc.$313GiftCash or cash equivalent2020
2020-12-10Aesculap, Inc.$245GiftCash or cash equivalent2020
2020-12-10Aesculap, Inc.$188GiftCash or cash equivalent2020
2020-12-10Aesculap, Inc.$185GiftCash or cash equivalent2020
2020-12-10Aesculap, Inc.$175GiftCash or cash equivalent2020
2020-12-10Aesculap, Inc.$168GiftCash or cash equivalent2020
2020-12-10Aesculap, Inc.$143GiftCash or cash equivalent2020
2020-12-10Aesculap, Inc.$92GiftCash or cash equivalent2020
2020-12-10Aesculap, Inc.$81GiftCash or cash equivalent2020
2020-12-10Aesculap, Inc.$70GiftCash or cash equivalent2020
2020-12-10Aesculap, Inc.$35GiftCash or cash equivalent2020
2020-12-10Aesculap, Inc.$26GiftCash or cash equivalent2020
2020-12-09Emergent BioSolutions Inc.$1,000GrantCash or cash equivalent2020
2020-12-08Alexion Pharmaceuticals, Inc.$31,598Research paymentCash or cash equivalentUltomiris Drug, ImmunologyA Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Rav2020
2020-12-08Karyopharm Therapeutics Inc.$1,872Research paymentCash or cash equivalentXPOVIO Drug, OncologyXPORT-COV-10012020
2020-12-08Karyopharm Therapeutics Inc.$888Research paymentCash or cash equivalentXPOVIO Drug, OncologyXPORT-COV-10012020
2020-12-07Abbott Laboratories$24,949Research paymentIn-kind items and servicesArchitect SARS-CoV-2 IgG Device, DiagnosticsSerum ImmunoGlobulin SIG-COVID investigation for COVID-19 healthcare workers at BMC2020
2020-12-04Adaptive Biotechnologies Corporation$2,250Research paymentIn-kind items and servicesclonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAP15542020
2020-12-03PFIZER INC.$10,010Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA2020
2020-12-03Janssen Research & Development, LLC$3,201Research paymentCash or cash equivalentRandomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez2020
2020-12-02Novo Nordisk Inc$75,027Research paymentCash or cash equivalentFIASP Drug, DiabetesComparison of post-prandial glycemic control in non-critically ill hospitalized patients with type 22020
2020-12-02PFIZER INC.$22,635Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-12-02VERTEX PHARMACEUTICALS INCORPORATED$10,000GrantCash or cash equivalent2020
2020-12-02Indivior Inc.$5,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentSUBLOCADE Drug, OUD2020
2020-12-01EMD Serono, Inc.$10,400Research paymentCash or cash equivalentTepotinib Drug, OncologyA Phase II, two-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic no2020
2020-12-01ViiV Healthcare Company$6,500Research paymentCash or cash equivalentA PHASE III, RANDOMIZED, MULTICENTER, OPEN-LABEL, NON-INFERIORITY STUD2020
2020-12-01ViiV Healthcare Company$4,225Research paymentCash or cash equivalentA PHASE III, RANDOMIZED, MULTICENTER, OPEN-LABEL, NON-INFERIORITY STUD2020
2020-12-01EMD Serono, Inc.$4,225Research paymentCash or cash equivalentTepotinib Drug, OncologyA Phase II, two-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic no2020
2020-12-01EMD Serono, Inc.$2,984Research paymentCash or cash equivalentTepotinib Drug, OncologyA Phase II, two-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic no2020
2020-12-01Merck Sharp & Dohme LLC$2,662Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A2020
2020-12-01EMD Serono, Inc.$2,600Research paymentCash or cash equivalentTepotinib Drug, OncologyA Phase II, two-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic no2020
2020-12-01EMD Serono, Inc.$1,300Research paymentCash or cash equivalentTepotinib Drug, OncologyA Phase II, two-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic no2020
2020-12-01ViiV Healthcare Company$1,300Research paymentCash or cash equivalentA PHASE III, RANDOMIZED, MULTICENTER, OPEN-LABEL, NON-INFERIORITY STUD2020
2020-12-01EMD Serono, Inc.$650Research paymentCash or cash equivalentTepotinib Drug, OncologyA Phase II, two-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic no2020
2020-11-28PFIZER INC.$16,499Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-11-26Intercept Pharmaceuticals, Inc.$4,890Research paymentCash or cash equivalentOCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY10118662020
2020-11-25PFIZER INC.$48,500GrantCash or cash equivalent2020
2020-11-25PFIZER INC.$2,500Charitable ContributionCash or cash equivalent2020
2020-11-24Novo Nordisk AS$2,251Research paymentCash or cash equivalentOzempic Drug, DiabetesNN9535-43522020
2020-11-23PFIZER INC.$96,569Research paymentCash or cash equivalentEVALUATION OF SEROTYPE 3 STRAINS COLLECTED FROM MASSACHUSETTS AND PORTUGUESE CHILDREN 200220182020
2020-11-23Gilead Sciences, Inc.$64,999Research paymentCash or cash equivalentLINC: Leveraging Informatics for NAFLD Care2020
2020-11-23PFIZER INC.$21,421Research paymentCash or cash equivalentEVALUATION OF SEROTYPE 3 STRAINS COLLECTED FROM MASSACHUSETTS AND PORTUGUESE CHILDREN 200220182020
2020-11-23Novo Nordisk AS$2Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522020
2020-11-23Novo Nordisk AS$2Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522020
2020-11-23Novo Nordisk AS$2Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522020
2020-11-23Novo Nordisk AS$2Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522020
2020-11-23Novo Nordisk AS$2Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522020
2020-11-21PFIZER INC.$30,169Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-11-20VERTEX PHARMACEUTICALS INCORPORATED$100,000GrantCash or cash equivalent2020
2020-11-20Merck Sharp & Dohme LLC$411Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A2020
2020-11-18PFIZER INC.$3,336Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA2020
2020-11-18Novo Nordisk Inc$2,893Research paymentCash or cash equivalentNovoLog Drug, DiabetesComparison of post-prandial glycemic control in non-critically ill hospitalized patients with type 22020
2020-11-18Novo Nordisk Inc$2,893Research paymentCash or cash equivalentFIASP Drug, DiabetesComparison of post-prandial glycemic control in non-critically ill hospitalized patients with type 22020
2020-11-17PFIZER INC.$40,111Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-11-17Conformis, Inc.$3,055Research paymentCash or cash equivalentiTotal CR Device, ORTHOPAEDIC KNEE IMPLANTSiTotal 12-0052020
2020-11-16Janssen Research & Development, LLC$50,890Research paymentCash or cash equivalentDARZALEX Biological, OncologyA Phase I-II Trial of Daratumumab for the Treatment of Patients with AL amyloidosis2020
2020-11-16Janssen Research & Development, LLC$440Research paymentCash or cash equivalentDARZALEX Biological, OncologyA Phase I-II Trial of Daratumumab for the Treatment of Patients with AL amyloidosis2020
2020-11-10Merck Sharp & Dohme LLC$2,826Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A2020
2020-11-09Bayer Healthcare Pharmaceuticals Inc.$3,826Research paymentCash or cash equivalentMirena Drug, Women's HealthBAY86-5028 Mirena extension contraception2020
2020-11-07PFIZER INC.$73,501Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-11-06Merck Sharp & Dohme LLC$9,087Research paymentIn-kind items and servicesGARDASIL 9 Biological, VACCINEAn Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose Vaccination Regimen over 6 months Amon2020
2020-11-06Novo Nordisk AS$41Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522020
2020-11-06Novo Nordisk AS$9Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522020
2020-11-05Alexion Pharmaceuticals, Inc.$18,482Research paymentCash or cash equivalentUltomiris Drug, ImmunologyA Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Rav2020
2020-11-05Medical Device Business Services, Inc.$795Research paymentCash or cash equivalentACTIS Device, Ortho-HipActis Total Hip System 2 Year Follow-up2020
2020-11-04Akcea Therapeutics, Inc.$12,071Research paymentCash or cash equivalentIST-2019-0601: Dr. Rick Ruberg - Lumbar Spinal Stenosis surgery hATTR pt screen2020
2020-11-03Alexion Pharmaceuticals, Inc.$5,000Research paymentCash or cash equivalentSoliris Drug, ImmunologySOLIRIS (eculizumab) for the Treatment of Participants with Coronavirus Disease 2019 (COVID-19) An Expanded Access Progr2020
2020-11-03Alexion Pharmaceuticals, Inc.$5,000Research paymentCash or cash equivalentUltomiris Drug, ImmunologyA Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Rav2020
2020-11-03Alexion Pharmaceuticals, Inc.$4,220Research paymentCash or cash equivalentSoliris Drug, ImmunologySOLIRIS (eculizumab) for the Treatment of Participants with Coronavirus Disease 2019 (COVID-19) An Expanded Access Progr2020
2020-11-03Alexion Pharmaceuticals, Inc.$2,600Research paymentCash or cash equivalentUltomiris Drug, ImmunologyA Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Rav2020
2020-11-03Alexion Pharmaceuticals, Inc.$2,600Research paymentCash or cash equivalentSoliris Drug, ImmunologySOLIRIS (eculizumab) for the Treatment of Participants with Coronavirus Disease 2019 (COVID-19) An Expanded Access Progr2020
2020-11-03Alexion Pharmaceuticals, Inc.$2,364Research paymentCash or cash equivalentUltomiris Drug, ImmunologyA Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Rav2020
2020-11-03Alexion Pharmaceuticals, Inc.$797Research paymentCash or cash equivalentUltomiris Drug, ImmunologyA Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Rav2020
2020-11-03Alexion Pharmaceuticals, Inc.$650Research paymentCash or cash equivalentSoliris Drug, ImmunologySOLIRIS (eculizumab) for the Treatment of Participants with Coronavirus Disease 2019 (COVID-19) An Expanded Access Progr2020
2020-10-31PFIZER INC.$82,460Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-10-30Medical Device Business Services, Inc.$500Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentDERMABOND Portfolio Device, Wound Closure2020
2020-10-29Regeneron Pharmaceuticals, Inc.$22,610Research paymentCash or cash equivalentA Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies fo2020
2020-10-29Regeneron Pharmaceuticals, Inc.$2,600Research paymentCash or cash equivalentA Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies fo2020
2020-10-28Abbott Laboratories$6,998Research paymentIn-kind items and servicesArchitect SARS-CoV-2 IgG Device, DiagnosticsSerum ImmunoGlobulin SIG-COVID investigation for COVID-19 healthcare workers at BMC2020
2020-10-27Novo Nordisk AS$5,495Research paymentCash or cash equivalentOzempic Drug, DiabetesNN9535-43522020
2020-10-26Richard Wolf Medical Instruments Corp.$10,000GrantCash or cash equivalent Device, Medical Center2020
2020-10-26Janssen Research & Development, LLC$5,005Research paymentCash or cash equivalentRandomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez2020
2020-10-23PFIZER INC.$51,399Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-10-23Novo Nordisk AS$246Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522020
2020-10-22Takeda Pharmaceuticals U.S.A., Inc.$754Research paymentCash or cash equivalentGATTEX Drug, INTERNAL MEDICINEA PROSPECTIVE, MULTI-CENTER REGISTRY FOR PATIENTS WITH SHORT BOWEL SYNDROME2020
2020-10-22Takeda Pharmaceuticals U.S.A., Inc.$754Research paymentCash or cash equivalentGATTEX Drug, INTERNAL MEDICINEA PROSPECTIVE, MULTI-CENTER REGISTRY FOR PATIENTS WITH SHORT BOWEL SYNDROME2020
2020-10-22Takeda Pharmaceuticals U.S.A., Inc.$754Research paymentCash or cash equivalentGATTEX Drug, INTERNAL MEDICINEA PROSPECTIVE, MULTI-CENTER REGISTRY FOR PATIENTS WITH SHORT BOWEL SYNDROME2020
2020-10-22Takeda Pharmaceuticals U.S.A., Inc.$754Research paymentCash or cash equivalentGATTEX Drug, INTERNAL MEDICINEA PROSPECTIVE, MULTI-CENTER REGISTRY FOR PATIENTS WITH SHORT BOWEL SYNDROME2020
2020-10-22Takeda Pharmaceuticals U.S.A., Inc.$754Research paymentCash or cash equivalentGATTEX Drug, INTERNAL MEDICINEA PROSPECTIVE, MULTI-CENTER REGISTRY FOR PATIENTS WITH SHORT BOWEL SYNDROME2020
2020-10-22Takeda Pharmaceuticals U.S.A., Inc.$754Research paymentCash or cash equivalentGATTEX Drug, INTERNAL MEDICINEA PROSPECTIVE, MULTI-CENTER REGISTRY FOR PATIENTS WITH SHORT BOWEL SYNDROME2020
2020-10-22Takeda Pharmaceuticals U.S.A., Inc.$78Research paymentCash or cash equivalentGATTEX Drug, INTERNAL MEDICINEA PROSPECTIVE, MULTI-CENTER REGISTRY FOR PATIENTS WITH SHORT BOWEL SYNDROME2020
2020-10-20Alexion Pharmaceuticals, Inc.$2,288Research paymentCash or cash equivalentSoliris Drug, ImmunologySOLIRIS (eculizumab) for the Treatment of Participants with Coronavirus Disease 2019 (COVID-19) An Expanded Access Progr2020
2020-10-20Alexion Pharmaceuticals, Inc.$2,288Research paymentCash or cash equivalentSoliris Drug, ImmunologySOLIRIS (eculizumab) for the Treatment of Participants with Coronavirus Disease 2019 (COVID-19) An Expanded Access Progr2020
2020-10-20Alexion Pharmaceuticals, Inc.$2,275Research paymentCash or cash equivalentSoliris Drug, ImmunologySOLIRIS (eculizumab) for the Treatment of Participants with Coronavirus Disease 2019 (COVID-19) An Expanded Access Progr2020
2020-10-20Alexion Pharmaceuticals, Inc.$2,275Research paymentCash or cash equivalentSoliris Drug, ImmunologySOLIRIS (eculizumab) for the Treatment of Participants with Coronavirus Disease 2019 (COVID-19) An Expanded Access Progr2020
2020-10-20Alexion Pharmaceuticals, Inc.$2,275Research paymentCash or cash equivalentSoliris Drug, ImmunologySOLIRIS (eculizumab) for the Treatment of Participants with Coronavirus Disease 2019 (COVID-19) An Expanded Access Progr2020
2020-10-20Alexion Pharmaceuticals, Inc.$1,426Research paymentCash or cash equivalentSoliris Drug, ImmunologySOLIRIS (eculizumab) for the Treatment of Participants with Coronavirus Disease 2019 (COVID-19) An Expanded Access Progr2020
2020-10-20Alexion Pharmaceuticals, Inc.$1,426Research paymentCash or cash equivalentSoliris Drug, ImmunologySOLIRIS (eculizumab) for the Treatment of Participants with Coronavirus Disease 2019 (COVID-19) An Expanded Access Progr2020
2020-10-19Regeneron Pharmaceuticals, Inc.$75,290Research paymentCash or cash equivalentA Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies fo2020
2020-10-17PFIZER INC.$3,336Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA2020
2020-10-15Bayer Healthcare Pharmaceuticals Inc.$956Research paymentCash or cash equivalentMirena Drug, Women's HealthBAY86-5028 Mirena extension contraception2020
2020-10-15Bayer Healthcare Pharmaceuticals Inc.$522Research paymentCash or cash equivalentMirena Drug, Women's HealthBAY86-5028 Mirena extension contraception2020
2020-10-14PFIZER INC.$70,488Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-10-09PFIZER INC.$95,526Research paymentCash or cash equivalentBIOTHERAPEUDIC TREATMENT FOR PATIENTS WITH CHRONIC KIDNEY DISEASE AND PRETEINURIA2020
2020-10-09Gilead Sciences, Inc.$65,000Research paymentCash or cash equivalentDetermining the Burden, Heritability, and Clinical Implications of Increased Liver Stiffness from Fatty Liver Disease in2020
2020-10-09PFIZER INC.$30,291Research paymentCash or cash equivalentDEVELOPING NEUTRALIZING SLIT23 MAB FOR TREATMENT OF GLOMERULAR DISEASES SUCH AS FOCAL SEGMENTAL GLOMERULOSCLEROSIS FSGS 2020
2020-10-07PFIZER INC.$67,789Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-10-07Indivior Inc.$5,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentSUBLOCADE Drug, OUD2020
2020-10-06Alexion Pharmaceuticals, Inc.$12,673Research paymentCash or cash equivalentUltomiris Drug, ImmunologyA Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Rav2020
2020-10-05Bioptics, Inc.$8,312Research paymentCash or cash equivalentTrident Device, Breast and Skeletal HealthTrident 2.02020
2020-10-03Indivior Inc.$5,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentSUBLOCADE Drug, OUD2020
2020-10-02Philips North America LLC$5,368Research paymentCash or cash equivalent(7881) Ultrasound Und Device, SleepLFQ Phase II2020
2020-10-01Celgene Corporation$6,609Research paymentCash or cash equivalentPhIII RPC1063 Open Label Extension Moderate to Severe in UC (RPC01-3102) (BMS Study Number: IM047-P23)2020
2020-10-01Janssen Research & Development, LLC$4,209Research paymentCash or cash equivalentRandomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez2020
2020-09-30PFIZER INC.$88,836Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-09-30Abbott Laboratories$3,900Research paymentIn-kind items and servicesArchitect SARS-CoV-2 IgM Device, DiagnosticsPerformance Evaluation of ARCHITECT SARS-CoV-2 IgM2020
2020-09-30Roche Diagnostics Operations, Inc.$1,911Research paymentCash or cash equivalentCD cobas Reagents Device, Centralized DiagnosticsRD0014692020
2020-09-30Abbott Laboratories$300Research paymentIn-kind items and servicesArchitect SARS-CoV-2 IgM Device, DiagnosticsPerformance Evaluation of ARCHITECT SARS-CoV-2 IgM2020
2020-09-30Abbott Laboratories$198Research paymentIn-kind items and servicesArchitect SARS-CoV-2 IgM Device, DiagnosticsPerformance Evaluation of ARCHITECT SARS-CoV-2 IgM2020
2020-09-29Merck Sharp & Dohme LLC$2,715Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A2020
2020-09-29E.R. Squibb & Sons, L.L.C.$1,200Research paymentCash or cash equivalentA PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF BMS-986036 (PEG-FGF22020
2020-09-29Novo Nordisk AS$41Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522020
2020-09-29Novo Nordisk AS$9Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522020
2020-09-28Merck Sharp & Dohme LLC$302Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A2020
2020-09-28Merck Sharp & Dohme LLC$190Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A2020
2020-09-26PFIZER INC.$121,349Research paymentCash or cash equivalentA PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC2020
2020-09-24Novo Nordisk AS$1,925Research paymentCash or cash equivalentOzempic Drug, DiabetesNN9535-43522020
2020-09-23Novo Nordisk AS$360Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522020
2020-09-23Novo Nordisk AS$360Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522020
2020-09-23Novo Nordisk AS$360Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522020
2020-09-23Novo Nordisk AS$360Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522020
2020-09-23Novo Nordisk AS$360Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522020
2020-09-23Novo Nordisk AS$360Research paymentIn-kind items and servicesOzempic Drug, DiabetesNN9535-43522020

The latest 200 records of 507.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

In Massachusetts; placed by its state only.

MeasureState
Massachusetts
Population B010037,044,056
Population, 2020 census P17,029,917
Median age B0100240.0
Under 18 B0100119.4%
65 and over B0100117.9%
Households B110012,785,042
Foreign born B0500218.0%
Median household income B19013$103,960
Median family income B19113$131,675
Per capita income B19301$57,897
Poverty rate B1700110.0%
Unemployment rate B230255.2%
Civilian labor force B230253,911,446
Mean commute (minutes) B0801329.1
Bachelor's degree or higher B1500347.3%
Housing units B250013,030,406
Owner-occupied B2500362.5%
Renters B2500337.5%
Median home value B25077$562,100
Median gross rent B25064$1,762
White, not Hispanic B0300266.6%
Black B030026.4%
Hispanic or Latino B0300213.3%
Asian B030027.3%
American Indian and Alaska Native B030020.1%

Economy now FRED unemployment 4.3% in Sep 2026 (4.6% a year earlier); per capita personal income $98,700 in 2025, up 27% in five years (+2.3% after inflation); Unemployment rate: 3.8% in Sep 2016 to 4.3% in Sep 2026; low 3.0%, high 17.8% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Massachusetts.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.